HomeAI · summaries
Storia in 2 fonti
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes has learned.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
forbes.com
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks to raise $400 million more VC funding at a $3.4…
- ·
qz.com
Pfizer licenses Chai Discovery AI platform for drug discovery
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor